Guardant Health’s InfinityAI Real-World Data Supports ENHERTU Approval in Japan
Event summary
- Guardant Health’s InfinityAI real-world evidence contributed to the approval of ENHERTU® for HER2-positive metastatic solid tumors in Japan.
- The approval was granted by Japan’s Ministry of Health, Labour and Welfare (MHLW) and supported by data from multiple clinical trials and InfinityAI.
- InfinityAI analyzed outcomes from a large cohort of patients with HER2 amplifications detected via Guardant360®, demonstrating significant unmet need.
- This collaboration highlights the role of real-world evidence in precision oncology and rare biomarker-defined populations.
The big picture
This approval underscores the growing importance of real-world evidence in complementing clinical trial data, particularly in rare biomarker-defined populations where traditional trial enrollment is limited. The collaboration between Guardant Health and Daiichi Sankyo sets a precedent for leveraging high-quality real-world data to support regulatory applications, potentially opening new pathways for targeted therapies in oncology.
What we're watching
- Regulatory Pathways
- How the integration of real-world evidence will influence future regulatory approvals in precision oncology.
- Market Expansion
- Whether Guardant Health can leverage this success to expand its partnerships with other biopharma companies.
- Data Utilization
- The pace at which real-world data platforms like InfinityAI will become standard in clinical trial optimization.
Related topics